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2 
ABSTRACT 28 
Background: Perfluoroalkyl substances (PFASs) have been frequently used for many years in industrial and 29 
consumer products. Maternal cigarette smoking may be associated with maternal PFAS levels. Further, 30 
prenatal exposure to PFASs is suggested impact on human fetal development and may have long-term 31 
adverse health effects later in life. Fetal exposure has previously been estimated from umbilical cord 32 
plasma, but the actual concentration in fetal organs has never been measured. 33 
Objectives: Concentrations of 5 PFASs and cotinine – the primary metabolite of nicotine – was measured in 34 
human fetuses, placentas, and maternal plasma to evaluate to what extend these compounds were 35 
transferred from mother to fetus, and to see if  PFAS concentration was associated with maternal cigarette 36 
smoking.    37 
Methods: A total of 39 Danish women who underwent legal termination of pregnancy before gestational 38 
week 12 were included; 24 maternal blood samples were obtained together with 34 placenta tissue and 39 
108 fetal organs. PFASs and cotinine were assayed by liquid chromatography/ triple quadrupole mass 40 
spectrometry.     41 
Results: In fetal organs perfluorooctanesulfonic acid (PFOS) 0.6 ng/g, perfluorooctanoic acid (PFOA) 0.2 42 
ng/g, perfluorononanoic acid (PFNA) 0.1 ng/g, perfluoroundecanoic acid (PFUnDa) 0.1 ng/g, and 43 
perfluorodecanoic acid (PFDA) 0.1 ng/g was detected. In fetal organs the mean concentrations of PFOS, 44 
PFOA, PFNA, and PFUnDA were reduced to 5—13% of the concentration found in maternal plasma; PFDA 45 
was reduced to 27%. A significant positive correlation was found between fetal age and fetal levels for all 46 
five PFASs evaluated. A significant positive correlation was also found between fetal age and fetal cotinine 47 
levels. A significant negative correlation was found between maternal BMI and maternal plasma PFNA and 48 
and PFUnDA concentrations. Smokers presented with 99 ng/g cotinine in plasma, 108 ng/g in placenta, and 49 
61 ng/g in fetal organs, non-smokers showed cotinine levels below 0.2 ng/g in all evaluated compartments. 50 
No correlation between maternal cotinine levels and PFASs levels were found. 51 
Conclusions: PFASs were transferred from mother to fetus, however with a markedly differently efficacy. 52 
The concentrations of PFOS, PFOA, PFNA, and PFUnDA in fetal organs were 7—20 times lower than 53 
maternal levels, whereas PFDA was four times lower. Furthermore, a significant correlation between fetal 54 
age and all evaluated PFASs was found. The health-compromising levels of these substances in fetal life are 55 
unknown.   56 
KEYWORDS: Prenatal exposure, perfluorinated compounds, cigarette smoke, maternal plasma, placenta 57 
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4 
Introduction 68 
Perfluoroalkyl substances (PFASs) are slowly degradable pollutants and belong to the group of water- and 69 
grease resistant fluorosurfactants used for many industrial and consumer applications, like outdoor clothes, 70 
non-stick cookware, food packaging, electronics, stain-resistant carpets and in fire-fighting foams (Key et 71 
al., 1997; Jensen and Leffers, 2008; De Solla et al., 2012). The PFASs include perfluorooctanesulfonic acid 72 
(PFOS), perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), perfluorodecanoic acid (PFDA) and 73 
perfluoroundecanoic acid (PFUnDA), all of which suspected to have negative impact on fetal growth and 74 
development and may disturb the endocrine system  ( de Cock et al., 2014; Johnson et al., 2014; Bach et al., 75 
2015 ). Prenatal exposure to PFOS and PFOA has been associated with an increased risk of congenital  76 
cerebral palsy in Danish boys (Liew et al., 2014) and maternal exposure to PFNA and PFDA has been 77 
associated with increased risk of pregnancy lost (Jensen et al., 2015). In rodents, prenatal exposure to high 78 
doses of PFOS and PFOA reduced postnatal survival and birth weight, and disturbed lactation and growth of 79 
the pups (Lau et al., 2004; Olsen et al., 2009) and both pre and postnatal PFASs exposure have been 80 
associated with hypothyroidism and significant decreased T4 levels in pups (Yu et al., 2009).  81 
PFASs, and particularly PFOA and PFNA, have been shown to induce synthesis of the estrogen-responsive 82 
biomarker protein vitellogenin leading to an estrogen-like activity in vivo in rainbow trout (Benninghoff et 83 
al., 2011).  84 
 85 
Notably, PFASs half-life in rats is as short as a few days (Kudo et al., 2002), compared to 200 days in the 86 
cynomolgus monkey (Seacat et al., 2002), and 2.5—4.5 years in humans (Olsen et al., 2007; Zhang et al., 87 
2013), suggesting a large difference in the elimination kinetics between species, and therefore animal 88 
models may only reflect the human situation to a limited extent.  89 
 90 
Human fetal exposure has been estimated from levels measured in maternal circulation and umbilical cord 91 
blood in newborns. Prenatal exposure to PFOA has been associated with decreased birth weight in a dose 92 
dependent manner (Johnson et al., 2014; Lauritzen et al., 2017). An association between PFOS exposure 93 
and birth weight has also been suggested, but reported results are conflicting (Bach et al., 2015) whereas 94 
prenatal PFOS and PFOA exposure has been suggested to negatively affect thyroid function. In new-born 95 
boys, T4 levels decreased with increasing prenatal exposure to PFOS and PFOA. Surprisingly, the same study 96 
found the opposite effect in girls where the T4 level increased with increasing prenatal exposure to PFOA 97 
(de Cock et al., 2014). In human breast cancer cells, PFOA are suggested to be cytotoxic and to exert an 98 
estrogen effect, though an anti-estrogen effect was found when cells were co-exposed to estradiol (Henry 99 
and Fair, 2013). Information on the actual concentration of PFASs in human tissues is limited, but a few 100 
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reports do exist (Olsen et al., 2003a; Maestri et al., 2006; Kärrman et al., 2010; Pérez et al., 2013). Lung 101 
tissue is suggested to accumulate the highest concentration of PFASs in general, though  PFOS and PFOA 102 
tend to accumulate with highest prevalence in liver and bone structures, respectively (Pérez et al., 2013). In 103 
liver, PFOS was detected in higher concentrations than PFOA (Maestri et al., 2006; Kärrman et al., 2010; 104 
Pérez et al., 2013). In human liver, PFOA has been detected in higher levels than PFNA and PFDA in one 105 
report (Pérez et al., 2013) and in similar levels in another (Kärrman et al., 2010). PFASs were found in all 106 
human tissues (Pérez et al., 2013). The tissue concentrations in human fetal organs are currently not 107 
available. 108 
 109 
Maternal cigarette smoking, together with other lifestyle parameters, may impact maternal PFAS levels 110 
(Lauritzen et al., 2016), why the present study included maternal smoking and other lifestyle factors in 111 
order to evaluate if maternal lifestyle affected maternal and fetal PFAS levels. Cotinine is the primary 112 
metabolite of nicotine and is a valid biomarker used to discriminate smokers from non-smokers (Benowitz 113 
et al., 2003). The adverse effects that maternal smoking has on the unborn child is well-known and widely 114 
described (Mund et al., 2013). Plasma cotinine concentrations in newborns have been reported to be 115 
approximately 60  ng/mL in children of heavy smokers, 30 ng/mL in children from moderate smokers, and 3 116 
ng/mL in children from non-smokers (Ivorra et al., 2014). The actual concentrations in human fetuses have 117 
not previously been measured. 118 
 119 
The present study is, to our knowledge, the first to measure the actual concentrations of PFASs and 120 
cotinine in human first trimester fetuses. These findings provide (i) important new knowledge on the 121 
perfusion of PFASs and cotinine from mother over the early placenta barrier to fetal circulation and organs, 122 
and (ii) evaluate if fetal age is associated with fetal PFASs levels indicating a fetal accumulation over time 123 
and (III) whether maternal cigarette smoking affects PFASs accumulation in mother and fetus. 124 
Materials and Methods 125 
2.1. Participating women 126 
The participants were healthy women aged 18-46 years (mean ±SEM, 26.4 ±1.1), who had decided to 127 
terminate pregnancy for other reasons than fetal abnormality. Exclusion criteria: age under 18 years, 128 
chronic diseases, dependency on an interpreter. The project was approved by the Research Ethics 129 
Committees of the Regional Capital (H-KF 01 258206); all participants received oral and written information 130 
and gave their informed consent. The participants answered a detailed questionnaire concerning lifestyle 131 
habits during pregnancy, including smoking and drinking habits. 132 
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2.2. Human fetal tissues and maternal blood samples 133 
Legal abortions were performed at the Department of Obstetrics and Gynaecology, University Hospital 134 
Skejby, Denmark and at Department of Obstetrics and Gynaecology, Regional Hospital Randers, Denmark, 135 
in collaboration with the Laboratory of Reproductive Biology, Rigshospitalet, Denmark. All fetuses were 136 
morphologically normal.  Within one hour after the surgical procedure the fetal organs and placenta tissue 137 
were isolated, washed in sterile saline snap frozen on dry ice, and stored at –80 °C until analysis. Fetal 138 
organs and placenta tissue processed for freezing more than one hour after collection were not included in 139 
the present study. Fetal age was measured by crown-rump lengths via ultrasound in connection with the 140 
surgical procedure. Gestational age was converted to age post conception by subtracting two weeks.  141 
Maternal blood samples were obtained in connection with anaesthesia prior to surgery, collected in 142 
ethylenediamine tetraacetic acid (EDTA) tubes, and kept on ice until centrifugation (4.000g for 15 min)  to 143 
isolate plasma. Plasma was aliquoted to 200 µl microinserts in 1.5 mL vials (Skandinaviska GenTec, Västra 144 
Frölunda, Sweeden) and stored at -20°C until analysis.   145 
 146 
2.3. Tissue processing 147 
Fetal- and placenta samples were homogenized in 70% acetonitril solution containing isotopically labelled 148 
cotinine and PFASs as internal standards (IS) with three parts solution and one part tissue. Homogenization 149 
was performed using a TissueLyser (Qiagen, Copenhagen, Denmark) with a 0.5 mm. stainless steel bead for 150 
one min. at 15 Hz, thereafter shaken at room temperature (RT) for 30 min. followed by 1600 g. 151 
centrifugation. The supernatant was transferred to 100 µl inserts fitted for 1.5 mL vials. The samples were 152 
transported at –20°C to the Division of Occupational and Environmental Medicine for further analysis. 153 
 154 
2.4. Analysis of PFASs and cotinine  155 
The analyses of PFOS, PFOA, PFNA, PFUnDa, PFDA and cotinine in the plasma, placenta and fetal tissues 156 
samples were performed by LC/MS/MS (QTRAP 5500; AB Sciex, Foster City, CA, USA coupled to a liquid 157 
chromatography system (UFLCXR, Shimadzu Corporation, Kyoto, Japan) according to procedures set out by 158 
Lindh et al. (Lindh et al., 2012). Plasma samples for calibration standards were obtained from healthy 159 
volunteers at the laboratory in Lund. Plasma was also used as a proxy matrix for the tissue samples. The 160 
levels were quantified and samples with low amounts of all compounds were selected for the calibration 161 
standards. Calibration standards were prepared by adding a standard solution containing all analyzed 162 
compounds. Concentrations were determined by peak area ratios between the analytes and the IS. The 163 
levels of all compounds in the pooled serum used for preparation of standards were quantified in each 164 
batch, and the calibration standards were corrected for the concentration found in this sample. Also, all 165 
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values were corrected for the chemical blank. The limit of detection (LOD) was determined as the 166 
concentration corresponding to three times the standard deviation of the ratio of the peak at the same 167 
retention time as the analyzed compounds, and the corresponding IS determined in the chemical blank 168 
samples. Tissue extraction time was tested for 5, 15, 30, 45 min. It was found that after 30 min. no 169 
additional chemicals were extracted from the tissue, and a 30 min. extraction time was subsequently used 170 
for all samples included in the present study. To make sure the study set-up was not contaminated with 171 
other chemicals, blank samples (IS solution) were included for all batches of tissue prepared and treated 172 
exactly the same way as the actual samples (see section 2.3.). No chemical contamination detected.  173 
Further quality-assurance analysis was not made due to limited fetal material.  174 
 175 
2.6. Statistical methods 176 
All statistical analyses were performed using GraphPad Prism 6.07 program (GraphPad Software, Inc., CA, 177 
USA) and RStudio program (RStudio software, Boston, Massachusetts, USA). Significance level was defined 178 
as a probability lower that 0.05 (p=0.05). An unpaired non-parametric t-test was used to compare PFA 179 
levels in plasma from smoking versus non-smoking women. Spearman’s rank test was performed to test for 180 
correlation between PFASs and cotinine, PFASs and fetal age, PFASs and lifestyle parameters. Additionally a 181 
linear regression model was used to test the potential correlations between the PFAS levels and lifestyle 182 
parameters, maternal and fetal ages. A pairwise correlation model was used to test if the lifestyle 183 
parameters correlated.   184 
 185 
2.7. Limitations 186 
A direct measurement of PFAS levels in fetal blood cannot be performed as it is not possible to obtain blood 187 
samples from fetuses at these early developmental stages. Fetal organs were used instead and their PFASs 188 
content compared to levels present in maternal circulation. Previously, PFOS have been measured in serum 189 
and liver tissue and a mean liver to serum ratio was reported to 1.3 to 1 in adults (34—70 years) (Olsen et 190 
al., 2003b). However, PFOS has been found in the higher concentration in liver compared to other organs 191 
(Pérez et al., 2013). Taken together, these finding suggest similar concentrations in serum and tissues and it 192 
is unlikely that the comparison between maternal plasma (mL) and fetal organs (g) significantly affects the 193 
results.  The number of fetal organs obtained from the same fetus was limited why a potential organ 194 
specific accumulation cannot be evaluated. 195 
 196 
Results  197 
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Thirty-nine women were included in this study and a total of 34 placenta samples, 108 fetal organs and 24 198 
blood samples were obtained from the participants (for detailed distribution see Fig. 1).  The 108 organs 199 
were obtained from a total of 36 fetuses aged 37—68 days pc (mean ±SEM, 52 ±1.3)(Fig. 1).  200 
 201 
3.1. Cotinine concentrations in plasma, placenta, and fetal organs 202 
A plasma cut-off value of  3 ng/mL was used to discriminate between smokers and non-smokers  (Benowitz 203 
et al., 2009).  Three participants reported themselves as non-smokers but presented with cotinine levels 204 
above the cut-off value. They were grouped as smokers and their questionnaire excluded from analysis. 205 
Women who smoked had significantly higher levels cotinine levels in maternal plasma, placenta, and fetal 206 
organs compared to non-smokers (p<0.001, p<0.0001, p<0.0001, respectively). Mean plasma levels (±SEM) 207 
in smokers were 99.3 ng/g ± 26.9, range: 6.2—326.1 ng/g, and in non-smokers 0.2 ng/g ± 0.1; range: 0—1.1 208 
ng/g (Table 2). Cotinine concentration in smoke-exposed placentas was 107.8 ng/g ±22.3; 3.8—374.7 (mean 209 
±SEM; range) and in non-exposed placentas 0.4 ng/g ±0.1; 0.0—1.8 (mean ±SEM; range) (Table 2). Cotinine 210 
levels in smoke-exposed and non-exposed fetal organs were 61.1 ng/g ±9.2; 1.1—336 (mean ±SEM; range) 211 
(p<0.0001) and 0.4 ng/g (range: 0—2.6), respectively (Table 2). Cotinine was detected in all different fetal 212 
organs exposed to cigarette smoke (Fig. 2). Cotinine was hardly detectable in the placentas and fetal organs 213 
of non-smokers (Fig. 2). In the group who smoked, a significant positive correlation was found between 214 
fetal age and the fetal to maternal cotinine ratio (p=0.0168) (Fig 3.). There were no association between the 215 
number of cigarettes smoked and the cotinine concentration in fetal tissue (p>0.1) (data not shown). 216 
Maternal plasma, placenta and fetal organs from the same women were available in 21 cases. From each 217 
woman, the mean cotinine concentration (ng/g) in fetal organs was calculated and the overall mean 218 
presented (Table 3). The percentage was calculated as concentrations in fetal organs and placenta 219 
respectively in relation to the corresponding maternal plasma (100%) (Table 3).  220 
3.2. PFASs concentrations in maternal plasma, placenta, and fetal organs 221 
Significant positive correlations between fetal age and the fetal to maternal ratio of all five PFASs were 222 
found: PFOS p=0.0008, 95% CI [0.33—0.86]; PFOA p=0.0246, 95% CI [0.06—0.77], PFNA p=0.0106, 95% CI 223 
[0.13—0.80]; PFUnDA p=0.0197, 95% CI [0.08—0.77]; PFDA p=0.0390, 95% CI [0.01—0.75] (Fig. 3). Further, 224 
significantly linear correlations were found for PFOS (p=0.0011), PFNA (p=0.0243), and PFUnDA (p=0.0467) 225 
(Fig. 3). 226 
The concentration of PFASs in maternal plasma, placenta, and fetal organs was presented in Table 2. The 227 
PFAS levels in plasma from women who smoked were higher compared to women who did not smoke, 228 
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though not at a significant level for any of the PFASs. All five measured PFASs were present in the evaluated 229 
fetal organs. No association between maternal plasma cotinine levels and plasma PFASs was found (p>0.1). 230 
 231 
Maternal plasma, placenta tissue and fetal organs were available for each of 21 cases. PFASs in placenta 232 
and fetal organs were greatly reduced compared to maternal plasma. The relative concentrations of PFOS, 233 
PFOA, PFNA, and PFUnDA in placentas were 11—15% of the concentration found in maternal plasma, and 234 
were further reduced to 5—13% in fetal organs (Table 3). PFDA was detected in relatively higher 235 
concentration in placenta (43%) and fetal organs (27%) compared the other PFASs (Table 3). PFOS in 236 
maternal plasma was significantly higher compared to the other PFASs measured. Interestingly, PFOS was 237 
detected in the lowest relative concentration in fetal organs (5%) (Table 3).  238 
 239 
3.3.  Correlation between lifestyle and PFAS levels 240 
Maternal characteristic and life-style habits were presented in Table 1. The concentrations of PFNA and 241 
PFUnDA showed a significant negative association with BMI (p=0.0391; p=0.0085, respectively) (Fig. 4), 242 
while there was no significant association between BMI and fetal PFASs levels (p>0.1) and between PFASs 243 
and maternal cigarette smoking, maternal age, or rual/urban residence (P>0.1). 244 
 245 
Further, a positive correlation (over 50%) was found between first-hand smoking and second-hand smoking 246 
(r=0.65, p<0.0001), second-hand smoke smoking also correlated positively with fathers smoking habits 247 
(r=0.50, p=0.004) (Supp. Table 1). Alcohol consumption correlated positively with soft drink consumption 248 
(r=0.57, p=0.0002) (Supp. Table 1). Use of over the counter medication correlated positively with use of 249 
prescription medicine (r=0.56, p=0.0003) (Supp. Table 1). There was no significant correlation between any 250 
other pairs of measured parameters (Supp. Table 1). 251 
 252 
4. Discussion 253 
These data demonstrate that PFASs and cotinine are transferred from mother to fetus during the first 254 
trimester of pregnancy and that fetal PFASs levels increase with fetal age, suggesting that these substances 255 
may accumulate in the fetus during gestation. All five evaluated PFASs were significantly higher in maternal 256 
circulation as compared to fetal levels. Further a negative correlation between maternal BMI and plasma 257 
concentrations of PFNA and PFUnDA were found supporting previous reports (Lauritzen et al., 2016). 258 
Collectively, these data provide information on the exact PFAS concentrations present in fetal organs, 259 
placenta, and maternal plasma during first trimester of pregnancy together with the transfer rate from 260 
mother to fetus.  261 
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4.1. Fetal age correlated positively with fetal concentrations of all five PFASs  262 
Fetal age correlated positively with fetal concentrations of all five PFASs evaluated, suggesting that these 263 
compounds accumulate in the fetal tissues and may continue to increase during pregnancy. It has been 264 
shown that phthalates and PFOS accumulate in the human amniotic fluid during the second trimester at 265 
almost 10% per gestational week (Jensen et al., 2012), supporting the present findings. Given that the 266 
development of keratinized epidermal skin is first seen in human fetuses from week 22 pc (Hardman et al., 267 
1999), the fetal skin will prior to this age be permeable and chemicals from the amniotic fluid may be 268 
absorbed by this route. Hence in early pregnancy the fetus may be exposed to PFASs from both placental 269 
blood and from the amniotic fluid. 270 
 271 
4.2. PFASs in human fetal organs in relation to maternal levels 272 
The five PFASs were detected in all the different fetal organs evaluated indicating that fetuses are 273 
systemically exposed to these compounds. Although the majority of the organogenesis are completed 274 
around weeks six to eight (Zhou et al., 2012), the organs are still  at  an early immature  stage, and an 275 
organ-specific accumulation is not expected at this early age. In adults, PFOA and PFOS accumulate in liver 276 
and bone structures (Pérez et al., 2013), further all the five PFASs evaluated in the present study have been 277 
detected in adult liver tissue (Kärrman et al., 2010) suggesting that the tissue accumulation the present 278 
study find in fetal life continues in adulthood.  279 
The concentrations of PFOS, PFOA, PFNA, and PFUnDA in placenta were reduced to 11—15% of the 280 
concentrations found in the maternal circulation. These levels were further attenuated across the placenta 281 
to the fetal organs, to a level of 5—13% of the concentration found in maternal plasmas, indicating that the 282 
fetal exposure to these compounds was 7—20 times lower than the maternal levels. Of the PFASs 283 
examined, PFDA were found in the lowest concentrations in maternal plasma, but showed the relative 284 
highest concentration in both placenta (43%) and fetal tissues (27%) as compared to maternal plasma. 285 
Although the assay of measurement is close to the detection limit, these values are within the standard 286 
curve and are considered valid. These data suggest that PFASs accumulate in fetal tissue with different 287 
efficiency. The differences in in fetal uptake may be due to different placental clearance or fetal age. 288 
Previously, fetal concentrations of PFOS, PFOA, and PFNA have been estimated  from the concentrations 289 
measured in the umbilical cord blood (Monroy et al., 2008; de Cock et al., 2014; Manzano-Salgado et al., 290 
2015). Our results help qualify estimations of fetal exposure by providing actual measured levels. The 291 
present study detected actual fetal concentration of PFASs to be 3—12 times lower than the previous 292 
estimated from umbilical cords, which may either reflect that fetal PFAS levels increase during gestation 293 
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(the present study find a significantly positive correlation between PFASs and fetal age), or indicate that the 294 
actual fetal exposure may be less than previously anticipated. 295 
4.3. PFAS levels in maternal plasma  296 
In maternal plasma, PFOS were present in the highest concentration of all PFASs measured followed by 297 
PFOA. The lowest concentrations were found in PFNA, PFUnDa, and PFDA, respectively. These findings 298 
were reflected in the levels measured in the fetal organs, where PFOS and PFOA also were preset in highest 299 
concentrations followed by PFNA, PFUnDa, and PFDA. The maternal PFAS levels support previous 300 
measurements from pregnant women (Monroy et al., 2008; Okada et al., 2013, 2014; Cho et al., 2015; 301 
Manzano-Salgado et al., 2015; Papadopoulou et al., 2015; Callan et al., 2016; Wang et al., 2016) except for 302 
PFUnDA, which has been detected both in higher and lower concentrations  (Okada et al., 2013; Callan et 303 
al., 2016; Wang et al., 2016). Literature is not conclusive with regards to the concentration of PFOS and 304 
PFOA in plasma. In a study of 1,400 women, plasma levels of PFOS and PFOA were 4 and 8 times higher 305 
than the present study (Fei et al., 2007) whereas Hannsen and colleagues  reported 5 and 1.5 times the 306 
concentrations of the present study (Hanssen et al., 2010). These differences may be explained by 307 
variations in local exposure or by the year in which the samples were taken; during the last decade 308 
changing levels of PFASs have been observed (Glynn et al., 2012; Olsen et al., 2012). 309 
We found a negative correlation between maternal BMI and the levels of PFNA and PFUnDA in maternal 310 
plasma, though the correlation disappeared when compared to fetal levels, suggesting that maternal BMI 311 
does not affect the PFNA and PFUnDA levels in the fetus. Maternal cigarette smoking was associated with 312 
slightly higher plasma concentration of all five PFASs, but not to a significant level. Conflicting results of the 313 
association between maternal cigarette smoking and maternal PFASs levels has been reported (Cho et al., 314 
2015; Lauritzen et al., 2016, 2017) and the effect of maternal cigarette smoke may be questionable. 315 
Nevertheless, this association was not reflected in placenta and fetal tissues, suggesting that smoking did 316 
not affect the levels of PFASs transferred to the fetus. The included women were recruited from both rural 317 
and urban areas, and no association was found between where the women were resident and her plasma 318 
levels of PFASs, suggesting that exposure to pollutants from urban living does not impact PFAS levels in 319 
pregnant women in Denmark.  320 
4.4. Health compromising PFASs levels 321 
Dietary intake has been suggested as the primary source of PFASs exposure (Domingo, 2012; Lauritzen et 322 
al., 2016) with the largest contribution coming from  meat, animal fat, and snacks (Halldorsson et al., 2008). 323 
The EFSA CONTAM panel has established a tolerable daily intake (TDI) for PFOS and PFOA of 150 ng/kg/day 324 
and 15 µg/kg/day, respectively, based on the lowest non-observed adverse effect level identified in animal 325 
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exposure studies. The estimated intake of PFOS and PFOA in the present study was 2.7 and 2.1 respectively, 326 
which is well below advised TDI.  In the Swedish adult population the mean dietary PFAS exposure has been 327 
estimated to 0.6—8.5 ng/kg/day (Domingo, 2012), which is also well below the estimated health 328 
compromising levels and suggests a minimal health risk at these levels in Scandinavian adults.  PFOS and 329 
PFOA plasma levels in Swedish women were 10.2 ng/mL and 2.9 ng/mL, respectively  (Axmon et al., 2014), 330 
which is slightly higher than the maternal plasma levels in the present study. This can be interpreted as 331 
neither the Swedish nor the present Danish plasma levels being health compromising in adult women, 332 
given that uptake from other sources than diet is insignificant. However, the health compromising levels of 333 
PFASs during fetal live is to our knowledge not defined. In pregnant women, plasma PFOA levels above 3.9 334 
ng/mL was significantly associated with reduced birth weight (Fei et al., 2007), suggesting that health 335 
compromising levels may be lower in fetal life compared to adulthood.   336 
 337 
4.5. PFASs and lifestyle 338 
We did not find a correlation between the evaluated self-reported lifestyle parameters except between 339 
smoking, second-hand smoke and fathers smoking habits, indicating that smokers are more likely to be 340 
surrounded by other smokers, and may therefore expose their fetus to more  cigarette smoke than their 341 
personal cigarette consumption indicates. For all other aspects the lifestyles of the participants were 342 
similar. The variation in PFAS concentrations between fetuses could not be explained by the monitored 343 
lifestyle parameters: smoking habits, coffee-, tea-, soft drink, soft drink light -consumption, or exercise. 344 
Fetal age was found to significantly correlate with PFAS levels in fetal organs and may be the most likely 345 
explanation for the variation between fetuses. Differences in placental clearance may also impact on the 346 
fetal PFAS levels. 347 
 348 
4.6. Cotinine concentration in maternal plasma, placenta, and fetal organs 349 
Among smokers, cotinine was detected in significantly higher concentrations in fetal organs compared to 350 
PFASs. Cotinine accumulated in placenta and 106% of the concentration found in maternal plasma was 351 
detected in placenta. The concentrations in smoke-exposed fetal tissues were reduced to 52% of the 352 
concentration found in maternal plasma, indicating that cotinine crosses the placenta relatively easy and 353 
reaches the fetal circulation. The mean concentration of cotinine in smoke-exposed fetuses was 61.1 ng/g, 354 
which was very close to the concentration previously measured in serum from newborns of heavy smokers 355 
(59.1 ng/mL) (Ivorra et al., 2014). This may indicate that even though cotinine reaches the fetus in high 356 
concentrations, its clearance is rapid (half-life: 16 hours, total clearance: 48 hours (Benowitz and Jacob, 357 
1994)) compared to PFASs (≈4 years). Where PFAS tends to accumulate in the fetus, cotinine levels may 358 
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rather reflect the actual maternal level, which diffuses to the fetus.  The highest cotinine concentration was 359 
detected in fetal liver, which was close to the same concentration found in the placenta, indicating that 360 
cotinine may accumulate in the liver. The lowest cotinine concentration was found in the ribs, likely 361 
reflecting that cotinine reaches more perfused organs easier than bone structures.  362 
 363 
5. Conclusions 364 
In conclusion, the present study provides actual measurements on PFASs and cotinine concentrations in 365 
human fetuses, together with comparisons to placenta and maternal plasma samples. Fetal age was 366 
positively correlated with all evaluated PFASs, suggesting a fetal accumulation over time. In maternal 367 
plasma PFOS levels were more than 4 times higher than PFOA, which were twice as high as PFDA, PFUnDa 368 
and PFDA. The PFOS, PFOA, PFNA, and PNUnDA levels were reduced in placenta to 11—15% of the 369 
concentration found in maternal plasma, and further reduced to 5—13%. In contrast PFDA, which was 370 
present in the lowest concentrations of the evaluated PFASs in maternal plasma, was detected in the 371 
relatively highest concentration in the fetus (27%), suggesting that the placenta retains PFASs with different 372 
efficiency. These data suggest that fetal PFAS levels increase with fetal age, though the health 373 
compromising level of these substances in fetal life is unknown.   374 
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Figure Legends: 520 
 521 
Figure 1. Study population, plasma and placenta samples, and fetuses included. 522 
Figure 2. Concentrations of cotinine and PFASs in maternal plasma (A) and in placenta and different fetal 523 
organs (B). Error bars represent min. and max. values. Maternal plasma cotinine (n=14); Cotinine NS: non-524 
smokers; S: Smokers; CT: Connective tissue.*Cotinine concentrations in fetuses exposed to maternal 525 
cigarette smoke (n=21).  526 
Figure 3. Mean concentration of PFOS and PFNA per fetus in relation to fetal age in days post conception 527 
(pc). Solid lines are unadjusted regression lines, dotted lines are error bars. A significant positive correlation 528 
between fetal age and PFOS and PFNA were found. 529 
Figure 4. Concentration of PFNA and PFUnDA in maternal plasma in relation to maternal body mass index 530 
(BMI). Solid lines are unadjusted regression lines, dotted lines are error bars. A significant positive 531 
correlation between fetal age and PFOS and PFNA were found. 532 
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